Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
9 evidence topics · 8 sources
Summary: anticipated place in treatment
VK2735 is investigational and has no approved indication. Guidelines place anti-obesity pharmacotherapy as an adjunct to lifestyle intervention: the AGA strongly recommends pharmacotherapy in addition to lifestyle intervention for adults with BMI of 30 or higher, or 27 or higher with weight-related complications, who have an inadequate response to lifestyle interventions, and the ADA names semaglutide or tirzepatide as the preferred agents for people with diabetes and overweight or obesity. The WHO guideline describes obesity as requiring “lifelong care”. The OMA and ACOFP describe family physicians as “often the first line of treatment”, and ICER expects that “much of the treatment of obesity, including prescribing medications, will be done by primary care clinicians”. Viking describes the subcutaneous formulation as suited to weight maintenance with every-other-week or monthly dosing after weekly induction, and the VANQUISH-1 extension will include these less-frequent regimens, with results anticipated in 2028. Viking describes the oral tablet as positioned to become the first oral dual GLP-1/GIP agonist to reach the market and expects many initial users of oral therapies to transition to subcutaneous administration. In a May 2024 national poll, 12% of U.S. adults reported ever taking a GLP-1 agonist and 6% reported current use.
Preferred pharmacotherapy in people with diabetes and overweight or obesity
“Obesity pharmacotherapy should be considered for people with diabetes and overweight or obesity along with lifestyle changes. Potential benefits and risks must be considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In people with diabetes and overweight or obesity, the preferred pharmacotherapy should be a glucagon-like peptide 1 receptor agonist or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with greater weight loss efficacy (i.e., semaglutide or tirzepatide)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obesity as a chronic disease requiring lifelong care
“The guidelines recognize obesity as a chronic, relapsing disease requiring lifelong care and emphasize early diagnosis and integrated, person-centered approaches combining behavioral, medical, surgical, and other interventions alongside prevention and management of comorbidities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary care as the care setting
“Family physicians are often the first line of treatment in the healthcare setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Barriers that impede optimal care of patients with obesity in primary care include failure to recognize obesity as a disease, lack of accurate diagnosis, insufficient access to obesity treatment resources, inadequate training, insufficient time, lack of adequate reimbursement and the adverse impact of bias, stigma, and discrimination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote